A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy Participants
Study Details
Study Description
Brief Summary
The purpose of this study is to assess safety and tolerability of multiple oral doses of GSBR-1290 (capsule) in healthy adult Japanese participants compared to non-Japanese participants.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1 |
Detailed Description
This is a multiple ascending dose (MAD) study in which 4 dose levels will be evaluated in 2 cohorts from Day 1 to Day 28 (4-week period). The starting dose of GSBR-1290 will be based on results from the single ascending dose (SAD) study (GSBR-1290-01) and MAD study (GSBR-1290-02 [NCT05762471]).
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Cohort 1: GSBR-1290 or Placebo Healthy Japanese participants will receive once daily doses of study drug (GSBR-1290 or placebo oral capsules) for up to 4 weeks. |
Drug: GSBR-1290
Participants will receive GSBR-1290 oral capsules.
Other Names:
Other: Placebo
Participants will receive matching placebo oral capsules.
|
Experimental: Cohort 2: GSBR-1290 Healthy non-Japanese participants (Caucasians or African Americans) will receive once daily doses of study drug (GSBR-1290 oral capsules) for up to 4 weeks. |
Drug: GSBR-1290
Participants will receive GSBR-1290 oral capsules.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Number of Participants With Adverse Events (AEs) and Serious AEs [From start of study drug up to End of study (EOS) (up to Day 42)]
- Number of Participants Based on Severity of AEs [From start of study drug up to EOS (up to Day 42)]
- Number of Participants With Clinically Significant Change From Baseline in Vital Signs [Baseline up to EOS (Day 42)]
- Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters [Baseline up to EOS (Day 42)]
- Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters [Baseline up to EOS (Day 42)]
Secondary Outcome Measures
- Analysis of Maximum Observed Plasma Concentration (Cmax) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate Pharmacokinetic (PK) Parameters [31 days]
- Analysis of Time to Maximum Observed Plasma Concentration (Tmax) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters [31 days]
- Analysis of Plasma Trough Concentrations for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters [31 days]
- Analysis of Area Under the Plasma Concentration-time Curve (AUC) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters [31 days]
Eligibility Criteria
Criteria
Inclusion Criteria:
For Cohort 1 only:
- Japanese participants must have both parents and 4 grandparents of Japanese origin
For Cohort 2 only:
- Non-Japanese participants must not have parents and grandparents of Japanese origin. Non-Japanese participants will be limited to Caucasians of European and Latin American descent or African Americans
For Cohorts 1 and 2:
-
Must have given written informed consent before any study-related activities are carried out
-
Adult males and females, age 18 to 55 years of age (inclusive) at screening
-
Body Mass Index (BMI) greater than or equal to (>=) 18.5 and less than or equal to (<=) 24.9 kilogram per square meter (kg/m^2), with a body weight (to 1 decimal place)
= 45.0 kg at screening
-
No nicotine use
-
Sitting blood pressure after resting for 5 minutes between 90 to 140 millimeter of mercury (mm Hg) systolic and 50 to 90 mm Hg diastolic and a heart rate between 40 to 100 beats per minute
-
Have suitable venous access for blood sampling
Exclusion Criteria:
-
History or presence of significant cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, or neurological disease, including any acute illness or major surgery within the past 3 months
-
Liver function test results elevated > 2.0-fold the upper limit of normal (ULN) for gamma-glutamyl transferase (GGT), alkaline phosphatase (ALP), aspartate transaminase (AST) or alanine transaminase (ALT). Bilirubin above ULN
-
Estimated glomerular filtration rate (eGFR) < 60 milliliter per minute (mL/min)/1.73m^2 body surface area
-
Known hypersensitivity to any of the study drug ingredients
-
Any other condition or prior therapy that would make the participant unsuitable for this study
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | ACT | Anaheim | California | United States | 92801 |
Sponsors and Collaborators
- Gasherbrum Bio, Inc
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- GSBR-1290-03